Janssen Search
Search results
Respiratory Infections
Respiratory Infections Article Type: Infectious Diseases & Vaccines By focusing on vulnerable populations, we aim to improve health for everyone across the globe. At Janssen, we have a deep heritage of caring for those affected by respiratory ...
New Long-Term Data from the CHRYSALIS Study Show Median PFS Not Reached after 33.6 Months of Follow Up with First-Line Use of RYBREVANT® (amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced NSCLC
Jun 04, 2023 United States Further analyses from the Phase 1/1b CHRYSALIS-2 study showed patients with osimertinib pre-treated EGFR-mutated lung cancer who have a MET positive biomarker had an overall response rate of 61 percent and a median PFS of 12.2 ...
What I Learned About DEI From Sweeping Floors
What a Whole Lot of Sweeping and a Little Bit of Vulnerability Taught Me about DEI Racial and social justice are not just buzzwords, they are crucial elements of public health. As Head of Diversity, Equity, and Inclusion (DE&I), Pharmaceuticals, R ...
Infectious Disease Treatment Development
Development Article Type: Infectious Diseases & Vaccines Exploring the potential of multiple treatment combinations to make a difference in patients' lives The Janssen Infectious Diseases & Vaccines multidisciplinary development team, ...
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
Jun 20, 2024 TREMFYA® Phase 3 Crohn's disease study achieves all primary and secondary endpoints SPRING HOUSE, Pa. (June 20, 2024) /PR Newswire/ – Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 ...
Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology Congress
Aug 27, 2024 United States Four RYBREVANT ® (amivantamab-vmjw) studies feature compelling new findings in lung and colorectal cancers New TAR-200 data reveal the potential of organ-sparing therapy for the treatment of bladder cancer RARITAN, NJ, August ...
Janssen Announces BALVERSA® (erdafitinib) Improved Overall Survival Versus Chemotherapy in Patients with Metastatic or Unresectable Urothelial Carcinoma and Selected Fibroblast Growth Factor Receptor Gene Alterations After Prior Anti-PD-(L)1 Treatment
Jun 05, 2023 United States Confirmatory Data from Cohort 1 of the Phase 3 THOR Study Showed Greater Than Four- Month Improvement in Median Overall Survival in Patients Treated with BALVERSA ® Versus Chemotherapy CHICAGO, June 5, 2023 – The Janssen ...
John (Jack) Lawrence, M.D.
JOHN (JACK) LAWRENCE, M.D. GLOBAL DEVELOPMENT HEAD CARDIOVASCULAR & METABOLISM John (Jack) Lawrence, M.D., is the Global Development Head of Cardiovascular & Metabolism (CVM) for Janssen Pharmaceutical Companies of Johnson & Johnson. Jack is ...
Landmark Phase 3 MARIPOSA Study Shows RYBREVANT® (amivantamab-vmjw) Plus Lazertinib Resulted in 30 Percent Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Oct 23, 2023 Spain Early data show an overall survival trend favoring the combination of RYBREVANT ® and lazertinib compared to osimertinib; consistent results seen in patients with and without brain metastases Late-breaking results from the MARIPOSA ...
Victories Over Cancer
Article Block Text: Our Cancer Scientists Give Their "Aha!" Moments Article Type: Oncology Research and Innovation This article, written by Ginny Graves, first appeared on jnj.com. One of the biggest health battles the world’s scientists are ...